Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06892691 · ClinicalTrials.gov registry record · NA

Pleuroscopy First Versus Thoracentesis First in Patients With Suspected Malignant Pleural Effusions

A NA study of Cancer and Pleural Effusion, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
NA
Development phase
98
Enrollment target
2
Study locations

NCT06892691 is a NA study of Cancer and Pleural Effusion that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 98 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06892691, a NA study of Cancer and Pleural Effusion, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
NA
Development phase
98 participants
Enrollment target
2
Study locations

Study Summary

This is a randomized control trial of patients with suspected malignant pleural effusions to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy) obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.

Conditions Studied

Interventions

  • PROCEDURE Pleuroscopy first
  • PROCEDURE Thoracentesis first

Study Locations (2)

New York

  • Mount Sinai West - New York
  • Mount Sinai Hospital - New York

Trial Details

FieldValue
Enrollment Target 98 participants
Start Date 2025-03-24
Est. Completion 2026-09-17
Phase NA

What the Registry Record Tells You About NCT06892691

The ClinicalTrials.gov registry entry for NCT06892691 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pleuroscopy first is the first listed.

NCT06892691 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06892691 about?

NCT06892691 is a clinical study titled "Pleuroscopy First Versus Thoracentesis First in Patients With Suspected Malignant Pleural Effusions". This is a randomized control trial of patients with suspected malignant pleural effusions to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy) obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.

What is the current status of trial NCT06892691?

This trial is currently recruiting. It is a NA study. The enrollment target is 98 participants. The study started on 2025-03-24. Estimated completion is 2026-09-17.

What conditions does trial NCT06892691 study?

This clinical trial studies the following conditions: Cancer, Pleural Effusion.

What interventions are being tested in trial NCT06892691?

The interventions under investigation include: Pleuroscopy first (PROCEDURE), Thoracentesis first (PROCEDURE).

Who is sponsoring clinical trial NCT06892691?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06892691 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.